|
JP3784076B2
(ja)
|
1997-02-07 |
2006-06-07 |
プリンストン ユニヴァーシティ |
変性ヌクレオチド三燐酸基質を利用できる組み換えタンパクキナーゼ
|
|
US6162613A
(en)
*
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
|
US7383135B1
(en)
|
1998-05-04 |
2008-06-03 |
Vertex Pharmaceuticals Incorporated |
Methods of designing inhibitors for JNK kinases
|
|
US6610483B1
(en)
*
|
1999-07-23 |
2003-08-26 |
Princeton University |
Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof
|
|
DE10024174A1
(de)
*
|
2000-05-17 |
2001-11-29 |
Gsf Forschungszentrum Umwelt |
Verfahren zum Selektieren von Inhibitoren für Enzyme
|
|
WO2002018604A2
(en)
*
|
2000-08-30 |
2002-03-07 |
The Salk Institute For Biological Studies |
Methods and compositions for determining isomerase enzymatic activity
|
|
US7285380B2
(en)
*
|
2000-12-15 |
2007-10-23 |
The Salk Institute For Biological Studies |
Methods of producing polyketide synthase mutants and compositions and uses thereof
|
|
EP1435957B1
(en)
|
2001-04-30 |
2009-06-17 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
|
|
US20060263800A1
(en)
*
|
2001-11-01 |
2006-11-23 |
Princeton University |
Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
|
|
WO2003105723A2
(en)
*
|
2002-06-14 |
2003-12-24 |
The Salk Institute For Biological Studies |
Mutant plant caffeic acid/5-hydroxyferulic acid 3/5-0-methyltransferases (comt), methods for preparation and use thereof
|
|
WO2004024082A2
(en)
*
|
2002-09-13 |
2004-03-25 |
Irm, Llc |
Highly specific modulators of gtpases for target validation
|
|
EA200500584A1
(ru)
*
|
2002-09-30 |
2006-02-24 |
Дженелэбс Текнолоджиз, Инк. |
Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
|
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
|
JP2007502772A
(ja)
|
2003-08-15 |
2007-02-15 |
メルク エンド カムパニー インコーポレーテッド |
４−シクロアルキルアミノピラゾロピリミジンｎｍｄａ／ｎｒ２ｂ拮抗薬
|
|
EP2283811A1
(en)
*
|
2004-10-19 |
2011-02-16 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Solid pharmaceutical composition comprising donepezil hydrochloride
|
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
|
WO2007044932A2
(en)
*
|
2005-10-13 |
2007-04-19 |
Activesite Pharmaceuticals |
Methods for indentification of inhibitors of enzyme activity
|
|
KR20130087054A
(ko)
*
|
2006-04-04 |
2013-08-05 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
|
US7890417B2
(en)
*
|
2007-01-31 |
2011-02-15 |
Bids Trading, L.P. |
Electronic block trading system and method of operation
|
|
WO2009046448A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
MX358640B
(es)
|
2008-01-04 |
2018-08-29 |
Intellikine Llc |
Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
|
|
WO2009102867A1
(en)
*
|
2008-02-12 |
2009-08-20 |
Bids Trading, L.P. |
Real-time portfolio balancing and/or optimization system and method
|
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン， エルエルシー |
キナーゼ阻害剤および使用方法
|
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
US9096611B2
(en)
|
2008-07-08 |
2015-08-04 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
|
JP5819195B2
(ja)
|
2008-10-16 |
2015-11-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
融合環ヘテロアリールキナーゼ阻害剤
|
|
US8476431B2
(en)
*
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
HRP20190016T1
(hr)
|
2009-08-17 |
2019-03-08 |
Intellikine, Llc |
Heterociklički spojevi i njihova upotreba
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
TWI546305B
(zh)
|
2011-01-10 |
2016-08-21 |
英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
|
EP2678018A4
(en)
|
2011-02-23 |
2015-09-30 |
Intellikine Llc |
COMBINATION OF CHINESE HEMMER AND USES THEREOF
|
|
WO2013012918A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
RU2015115631A
(ru)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Модулирование ire1
|
|
CN105102000B
(zh)
|
2012-11-01 |
2021-10-22 |
无限药品公司 |
使用pi3激酶亚型调节剂的癌症疗法
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
US9724354B2
(en)
|
2013-03-22 |
2017-08-08 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
|
|
US10769725B1
(en)
|
2013-06-05 |
2020-09-08 |
Bids Trading, L.P. |
System and methods for optimizing the effectiveness of interaction between participants in an electronic trading environment
|
|
MX389256B
(es)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EA201691872A1
(ru)
|
2014-03-19 |
2017-04-28 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
EP3801069A4
(en)
|
2018-06-01 |
2022-03-16 |
Cornell University |
MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
|
|
US20230121698A1
(en)
*
|
2019-12-23 |
2023-04-20 |
Sanford Burnham Prebys Medical Discovery Institute |
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
|
|
US12215108B2
(en)
|
2022-01-10 |
2025-02-04 |
Southern Research Institute |
Development of potential antidotes for arsenicals
|